Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15788337 | 1.00 | SLC17A5 (0.54) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL1486194 | 0.89 | SLC17A5 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL29398108 | 0.89 | SLC17A5 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL15788339 | 0.89 | MDM4 (0.47) | SLC17A5CASP3MDM4TP53MDM2 | |
| SCHEMBL15788338 | 0.89 | MDM4 (0.47) | SLC17A5CASP3MDM4TP53MDM2 | |
| SCHEMBL19888241 | 0.85 | SLC17A5 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL1001473 | 0.85 | MDM4 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL3436129 | 0.85 | MDM4 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL29400770 | 0.85 | MDM4 (0.58) | SLC17A5CASP3MDM4TP53TLR2 | |
| SCHEMBL118051 | 0.85 | MDM4 (0.60) | CASP3MDM4TP53TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | SLC17A5 445/4885CASP3 713/4885MDM4 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.